Skip to main content

Table 2 Operative and post-operative characteristics (management and laboratory) of coronary artery bypass patients according to neutrophil lymphocyte ratios (NLR) and surgical approach (MICS vs. Sternotomy CABG)

From: Elevated preoperative neutrophil/lymphocyte ratio as a predictor of increased long-term survival in minimal invasive coronary artery bypass surgery compared to sternotomy

Variables

NLR <2.3 (N = 371)

p Value

2.3 ≤ NLR ≤ 3.4 (N = 375)

p Value

NLR >3.4 (N = 380)

p Value

 

Sternotomy CABG

MICS

 

Sternotomy CABG

MICS

 

Sternotomy CABG

MICS

 

n

242

129

 

245

130

 

243

137

 

In-hospital medication

        

Aspirin

238 (98.3%)

128 (99.2%)

0.66

234 (95.9%)

130 (100%)

0.02

237 (97.5%)

137 (100%)

0.09

Clopidogrel

110 (45.5%)

111 (86.0%)

<0.001

128 (52.5%)

115 (88.5%)

<0.001

120 (49.4%)

116 (84.7%)

<0.001

Beta-blockers

232 (95.9%)

124 (96.1%)

0.91

230 (94.3%)

128 (98.5%)

0.06

231 (95.1%)

135 (98.5%)

0.08

Angiotensin convertase inhibitor

84 (34.7%)

44 (34.1%)

0.91

96 (39.3%)

31 (23.8%)

0.00

104 (42.8%)

45 (32.8%)

0.06

Angiotensin receptor blocker

29 (12.0%)

13 (10.1%)

0.58

17 (7.0%)

13 (10.0%)

0.30

19 (7.8%)

17 (12.4%)

0.14

Warfarin

18 (7.4%)

7 (5.4%)

0.46

18 (7.4%)

8 (6.2%)

0.66

26 (10.7%)

9 (6.6%)

0.18

Statin

232 (95.9%)

127 (98.4%)

0.23

229 (93.9%)

126 (96.9%)

0.20

228 (93.8%)

132 (96.4%)

0.29

Medication on discharge

        

Aspirin

237 (98.3%)

125 (97.7%)

0.70

234 (95.9%)

127 (97.7%)

0.56

230 (95.4%)

131 (97.8%)

0.26

Clopidogrel

66 (27.4%)

101 (78.9%)

<0.001

83 (34.0%)

105 (80.8%)

<0.001

64 (26.6%)

104 (77.6%)

<0.001

Beta-blockers

212 (88.0%)

114 (89.1%)

0.76

216 (88.5%)

117 (90.0%)

0.66

208 (86.3%)

123 (91.8%)

0.11

Angiotensin convertase inhibitor

70 (29.0%)

32 (25.0%)

0.41

67 (27.5%)

24 (18.5%)

0.05

75 (31.1%)

27 (20.1%)

0.02

Angiotensin receptor blocker

1 (0.4%)

4 (3.1%)

0.05

4 (1.7%)

1 (0.8%)

0.66

2 (0.8%)

7 (5.2%)

0.01

Warfarin

30 (12.4%)

17 (13.3%)

0.82

27 (11.1%)

12 (9.2%)

0.58

43 (17.8%)

11 (8.2%)

0.01

Statin

220 (91.3%)

119 (93.0%)

0.57

222 (91.0%)

120 (92.3%)

0.66

218 (90.5%)

123 (91.8%)

0.67

Operative data

         

Internal mammary artery utilized

231 (95.5%)

127 (98.4%)

0.23

230 (94.3%)

128 (97.7%)

0.13

221 (90.9%)

134 (97.8%)

0.01

Number of conduits used for bypass

3.28 ± 0.991

2.12 ± 0.673

<0.001

3.26 ± 0.886

2.28 ± 0.806

<0.001

3.12 ± 0.910

2.17 ± 0.753

<0.001

Cardiopulmonary bypass

27 (11.2%)

6 (4.7%)

0.04

30 (12.3%)

7 (5.3%)

0.03

18 (7.4%)

8 (5.8%)

0.56

Postoperative complications

        

Renal Failure on Dialysis

1 (0.4%)

2 (1.6%)

0.28

3 (1.2%)

4 (3.1%)

0.25

12 (4.9%)

3 (2.2%)

0.19

New onset atrial fibrillation

33 (13.6%)

22 (17.1%)

0.38

40 (16.4%)

30 (22.9%)

0.12

48 (19.8%)

43 (31.4%)

0.01

Septicemia

0 (0%)

5 (3.9%)

0.005

0 (0%)

2 (1.5%)

0.12

6 (2.5%)

2 (1.5%)

0.72

  1. Categorical variables were presented as frequencies and percentages; continuous variables were presented as means and standard deviations. CABG  coronary artery bypass grafting.